RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
Clinical trial NCT06328777 · RECRUITING
Trial details
- NCT number
- NCT06328777
- Sponsor
- Cabaletta Bio
- Status
- RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-07-02
- Primary completion
- 2029-07-01
- Enrollment
- 37
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.